Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

DXCM · Q1 2026 Earnings

Dexcom

Reported April 30, 2026

30-second summary

Dexcom opened FY2026 with Q1 revenue of $1.192B (+15% YoY reported, +12% organic) and non-GAAP EPS of $0.56 (+75% YoY), then raised FY non-GAAP operating margin guidance to 23–23.5% (from 22–23%) and Adjusted EBITDA margin to 31–31.5% (from 30–31%) while holding the revenue and gross margin guides unchanged. The signal is that the margin-expansion thesis is tracking ahead of plan after a single quarter — not a top-line reacceleration, but durable operating leverage being pulled forward into the guide.

Headline numbers

EPS

Q1 FY2026

$0.56

+19.1% vs est.

Revenue

Q1 FY2026

$1.19B

+15.0% YoY

+1.9% vs est.

Gross margin

Q1 FY2026

62.9%

Operating margin

Q1 FY2026

21.4%

Key financials

Q1 FY2026

Metric	Q1 FY2026	YoY	Q4 FY2025	QoQ
Revenue	$1.19B	+15.0%	$1.26B	-5.4%
EPS	$0.56	—	$0.68	-17.6%
Gross margin	62.9%	—	62.9%	+0bps
Operating margin	21.4%	—	25.6%	-420bps

Guidance

Dexcom reaffirmed full-year FY2026 revenue guidance at $5.16-$5.25B (11-13% growth) while raising operating margin and Adjusted EBITDA margin guidance by 50-150 bp, signaling confidence in executing operating leverage despite holding top-line steady.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Revenue	Q1 FY2026	—	$1.192 billion	+1.9% above estimate; +15% YoY	Beat
Non-GAAP EPS	Q1 FY2026	—	$0.56	+19.1% above consensus estimate of $0.47	Beat

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Non-GAAP Operating Margin	FY2026	22-23%	23-23.5%	+50-150 bp (range raised at both ends)	Raised
Adjusted EBITDA Margin	FY2026	30-31%	31-31.5%	+50-150 bp (range raised at both ends)	Raised

Reaffirmed unchanged this quarter: Revenue ($5.16 - $5.25 billion), Non-GAAP Gross Profit Margin (63-64%)

Other KPIs

Q1 FY2026

Segment	Q1 FY2026	YoY
United States	$0.832B	+11.0%
International	$0.36B	+26.0%
Organic Revenue Growth	12%	—
Non-GAAP Gross Profit Margin	63.5%	—
Non-GAAP Operating Margin	22.2%	—
Adjusted EBITDA Margin	30.6%	—
Cash and Marketable Securities	$2.42 billion	—

Management tone

Type 2 non-insulin has been promoted to an active growth engine with a quantified near-term commercial pipeline. Management states "This puts us on track to have commercial coverage for more than 7 million type 2 non-insulin lives by the end of this year" and "By the end of the year, that's going to add another million lives to that non-insulin-using population." Commercial coverage wins are doing the work the FY26 base case did not assume, and CMS is now framed as additional asymmetric upside on top of an active commercial expansion.

15-day G7 is framed as a product-market-fit inflection with measurable retention impact. The CFO anchored 15-day on a customer satisfaction step-change: "our MPS scores have jumped up with 15 day. And we saw that playing out in the first quarter that is sustainable, right?" with a quantified target of "nearly 50% will be converted by the end of the year over to this new 15-day product." This positions 15-day as a retention/utilization lever, not just a wear-length feature.

The CMS Type 2 NIT pathway may not require the RCT readout. Jake stated "At this point in time, the RCT may not be required for that CMS coverage. I think in my conversations with the folks at CMS, it's very clear that they understand the benefit of CGM for this category" and characterized the timing as "really just a matter of time." A coverage decision now plausibly precedes the trial, which materially shortens the asymmetric-upside timeline against the FY26 base case.

Operating expense discipline drove the margin raise. The CFO framed the raise as: "our strong cost control over the quarter positioned us to raise our full-year non-GAAP operating profit and adjusted EBITDA margin guidance." With gross margin held back as a geopolitical reserve, the operating margin raise is underwritten by OpEx leverage rather than gross margin upside.

The margin guide raise contains one defensive note worth flagging. The CFO explicitly stated they "left gross margin guidance unchanged to account for the current geopolitical environment" and quantified the fuels/resins risk at "about 50 to 100 basis points." If gross margin holds at 63.5%+ through Q2 without geopolitical disruption, there is implicit room for a second guide raise — the CFO noted "absent that, we would be raising the gross margin guidance."

Recurring themes management leaned on this quarter:

Type 2 non-insulin market expansion as primary near-term growth driverG7 15-day product transition and customer satisfaction inflectionGross margin expansion despite inflationary headwinds (oil/resin)International market share gains through targeted reimbursement winsStello redesign as customer engagement and retention leverCMS Type 2 non-insulin coverage imminent but timing uncertain

Risks management surfaced:

Geopolitical environment uncertainties with fuel prices and shipping routes (50-100 bps gross margin risk)Forward-looking statements subject to risks and uncertainties detailed in SEC filingsU.S. market growth dependent on coverage expansion timingInternational competitive and tender dynamicsTiming and terms of CMS Type 2 non-insulin coverage decision

Answers to last quarter's watch list

Q1 FY2026 U.S. growth trajectory off the Q4 +11% print — U.S. revenue grew +11% in Q1. Sell-through did not visibly reaccelerate, but it also did not roll over; the FY 11–13% guide is intact with international carrying the upside. Status: Continue monitoring

Gross margin walk toward 63–64% and Ireland OpEx cadence — Non-GAAP gross margin printed 63.5% in Q1, already at the high end of the FY 63–64% guide. The operating margin guide raise of +75bps at the midpoint signals OpEx absorption is tracking better than planned. Status: Resolved positively

Type 2 non-insulin RCT readout and CMS signaling — Management now states the RCT may not be required for CMS coverage and characterizes the decision as "just a matter of time," with the commercial side already on track for 7M covered lives by year-end. No coverage decision yet, but the path has materially shortened. Status: Continue monitoring (with a meaningfully reduced gating risk)

International revenue growth — International grew +26% YoY reported and +17% organic in Q1, with widespread strength across core markets. Status: Resolved positively

Capital allocation cadence post-convertible settlement — Cash and marketable securities rose to $2.42B, up over $400M from year-end 2025, but the press release does not separately disclose buyback activity for Q1. Status: Not resolved

Stelo separate-line disclosure and run rate — Stelo was not broken out as a discrete revenue line in the figures provided this quarter. Status: Not resolved

Smart Basal early-access traction — Management confirmed Smart Basal remains in pilot launch, focused on workflow integration across endo, large diabetes clinics, and primary care, with a broader launch planned later in the year. Status: Continue monitoring

What to watch into next quarter

Whether U.S. growth steps up from +11% toward +13%+ in Q2 — Q1 U.S. growth of +11% against a FY 11–13% guide leaves limited room for H2 deceleration; either Type 2 NIT commercial wins (Prime Therapeutics adds ~1M lives by year-end) or 15-day retention needs to drive a Q2 acceleration, or the FY guide skews to the low end.

Gross margin sustaining 63.5%+ in Q2 without geopolitical disruption — the CFO held the gross margin guide back as a 50–100bps fuels/resins reserve; a clean Q2 print at or above 63.5% sets up a second margin guide raise on the Q2 call.

Any CMS Type 2 NIT coverage signaling ahead of the RCT readout — management has now positioned the RCT as potentially unnecessary; any draft coverage decision or memo from CMS before Q2 print is asymmetric upside against the FY26 base case.

15-day conversion tracking toward the "nearly 50% by year-end" target — this is the first explicit quantified milestone for the 15-day platform; a Q2 update materially below ~25–30% conversion would call the retention-driven thesis into question.

International organic growth holding above +15% — the +17% organic Q1 print needs to sustain against tougher H2 comps to defend the medium-term TAM reframe.

Buyback cadence disclosure — with the convertible behind it and cash rebuilding to $2.42B (+$400M QoQ), the absence of buyback disclosure in the Q1 release leaves capital allocation unresolved; the Q2 release should clarify.

Type 2 non-insulin RCT readout at ADA 2026 Scientific Sessions — Jake confirmed the full readout will occur at ADA in the coming weeks; results powered for A1C reduction would form the cornerstone evidence base for global payers.

Sources

Dexcom Q1 2026 press release (Exhibit 99.1), filed with SEC: https://www.sec.gov/Archives/edgar/data/1093557/000109355726000072/dxcm3312026-exhibit991.htm
Dexcom Q1 2026 earnings conference call, prepared remarks and Q&A (CEO Jake Leach and CFO Jeremy Sylvain).

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.